ASCO Highlights Recommendations for Management of the 10 Most Common Immune-Related Adverse Events with Immune Checkpoint Inhibitors
The first immune checkpoint inhibitor, ipilimumab, was approved by the FDA for the treatment of advanced melanoma in 2011. Since then, seven more (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, dostarlimab, and cemiplimab) have become available for the treatment of around 17 different types of cancer (as of December 2021). It was estimated that in 2018, over 40% of cancer patients in the US were eligible for treatment with immune checkpoint inhibitors and this proportion is likely to have increased since that time due to the rapid expansion of indications approved for these agents. ...
Advertisement
Advertisement
Advertisement
Advertisement
Our Authors